Paclitaxel (Taxol)-induced Gene Expression and Cell Death Are Both Mediated by the Activation of c-Jun NH 2 -terminal Kinase (JNK/SAPK) by Lee, Li Fen et al.
Paclitaxel (Taxol)-induced Gene Expression and Cell Death
Are Both Mediated by the Activation of c-Jun NH2-terminal
Kinase (JNK/SAPK)*
(Received for publication, May 26, 1998, and in revised form, August 1, 1998)
Li-Fen Lee‡§, Guoxuan Li§, Dennis J. Templeton¶, and Jenny P.-Y. Ting§i**
From the Departments of ‡Biology, iMicrobiology and Immunology, and the §Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295, and the ¶Institute of Pathology,
Case Western Reserve University, Cleveland, Ohio 44106
Paclitaxel (Taxol) is a novel anti-cancer drug that has
shown efficacy toward several malignant tumors, par-
ticularly ovarian tumors. We reported previously that
paclitaxel can induce interleukin (IL)-8 promoter acti-
vation in subgroups of ovarian cancer through the acti-
vation of both AP-1 and nuclear factor kB. Further anal-
ysis of paclitaxel analogs indicates that the degree of
IL-8 induction by analysis correlates with the extent of
cell death; however, IL-8 itself is not the cause of cell
death. This suggests that pathways that lead to IL-8 and
cell death may overlap, although IL-8 per se does not kill
tumor cells. To decipher the upstream signals for pacli-
taxel-induced transcriptional activation and cell death,
we studied the involvement of protein kinases that lead
to the activation of AP-1, specifically the c-Jun NH2-
terminal kinase (JNK1), p38, and the extracellular sig-
nal-regulated kinase 1 (ERK1). The role of IkB in pacli-
taxel-induced cell death was also analyzed. Paclitaxel
activated JNK, and to a lesser degree p38, but not ERK1.
Paclitaxel-induced IL-8 promoter activation was inhib-
ited by dominant-inhibitory mutants of JNK, p38, and
the super-repressor form of IkBa, but not by dominant-
inhibitory forms of ERK1. Dominant-inhibitory mutants
of JNK1 also greatly reduced paclitaxel-induced cell
death, and the kinetics of JNK induction was closely
followed by DNA fragmentation. These results indicate
(i) that paclitaxel activates the JNK signaling pathway
and (ii) that JNK activation is a common point of pacli-
taxel-induced gene induction and cell death.
Paclitaxel (Taxol) is a new generation of chemotherapeutic
drug that is effective against malignant non-small cell lung (1,
2), prostate (3, 4), and breast cancer (5), with the most encour-
aging effects observed in cancer chemotherapy-refractory ovar-
ian cancer (6). Paclitaxel exhibited significant antitumor activ-
ity against human ovarian cancer in a nude mouse model (6).
Furthermore, paclitaxel significantly inhibited the angiogenic
response induced by tumor cell supernatant in mice (7, 8). The
primary mechanism of action of paclitaxel is attributed to its
ability to bind microtubules and to prevent their disassembly.
However, the effect of paclitaxel exceeds that of conventional
microtubule-disrupting agents, and there is increasing evi-
dence that paclitaxel has multiple cellular effects in addition to
the blockage of mitosis (9–15).
One of the effects of paclitaxel is to alter gene expression. In
murine macrophages, paclitaxel can induce the expression of a
series of lipopolysaccharide-inducible cytokines, such as IL1
-1a, IL-1b, TNF-a, and interferon-inducible protein 10 (9–12,
16). In human monocytes, paclitaxel also induces cytokine syn-
thesis (17). Most pertinent to this report, paclitaxel can induce
IL-8 gene expression at the transcriptional levels in subsets of
human ovarian cancer lines (14). This induction is mediated by
the activation of NF-kB and AP-1 transcription factors, which
bind to cognate sites in the IL-8 promoter. Gel shift assays
show that paclitaxel caused a marked increase in protein bind-
ing to AP-1 and NF-kB cognate sequences in paclitaxel-respon-
sive cells but not in nonresponsive cells (15). However, little is
known about the upstream signaling events that lead to the
activation of these transcription factors in response to pacli-
taxel. The present study identifies upstream signals that are
activated by paclitaxel and mediate its effects. Identification of
upstream signals involved in IL-8 gene induction may have
broad ramifications because a tight correlation between the
ability of paclitaxel analogs to induce IL-8 and cell death
among ovarian tumors has been observed previously (18). It is
important to determine if the same signals that induce IL-8
gene induction also induce cell killing.
Mitogen-activated protein kinases (MAPKs) are serine/thre-
onine kinases that mediate numerous types of extracellular
stimuli (19, 20). The ERK member of MAPK is activated by
growth factor via a Ras-dependent signal transduction path-
way (21). ERK can phosphorylate and activate various tran-
scription factors, including c-Myc and TCF/Elk1 (22). In con-
trast, the JNK (JNK1 and JNK2) members of MAPKs, also
designated stress-activated protein kinases (SAPKs), can be
activated by proinflammatory cytokines (23–25) and environ-
mental stress such as UV light (26, 27), g-irradiation (26), heat
shock, osmotic shock (28), shear stress (29), growth factor with-
drawal (30), ceramide (31), and protein synthesis inhibitor (23).
The activation of the JNK cascade is also observed in cells
stimulated by various mitogenic factors such as growth factors,
oncogenic Ras, phorbol ester, and T-cell activation signaling
(32, 33). Like MAPK, JNK activation requires phosphorylation
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at two conserved residues, threonine and tyrosine, by the MAP
kinase kinase SEK1/MKK4/JNK kinase (34). The latter is in
turn phosphorylated by upstream kinase MAPK kinase kinase
1 (MEKK1) (32, 35). The JNK kinase cascade was shown to be
a common pathway involved in cell proliferation and stress-
response signaling. There are at least three major transcription
factors that can be phosphorylated by JNK: c-Jun (36), ATF-2
(37), and TCF/Elk1 (38).
In this report we demonstrate that JNK is strongly activated
by paclitaxel, a chemotherapeutic agent. The activation of JNK
occurs in a dose- and time-dependent manner. The inhibition of
JNK activity greatly reduced paclitaxel-induced IL-8 gene ex-
pression and cell death, whereas the inhibition of p38 produced
a smaller but noticeable effect. These results show the involve-
ment of JNK and p38 in paclitaxel-induced IL-8 transcription
activation and in mediating cell death, both of which have
anti-tumor affects.
MATERIALS AND METHODS
Cells, Antibodies, and Reagents—The human ovarian cancer cell line
OVCA 420 (a gift from Dr. Robert Bast, Jr., M. D. Anderson, Houston,
TX) was maintained as monolayer cultures in Dulbecco’s modified Ea-
gle’s medium/F-12 medium supplemented with 5% fetal bovine serum.
The derivation of these cells has been described previously (39). Rabbit
anti-JNK1, anti-ERK1, and anti-p38 antibodies were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The monoclonal anti-
body M2 was obtained from IBI-Kodak (New Haven, CT). Anti-c-Jun
and anti-c-Fos were purchased from Santa Cruz Biotechnology. Myelin
basic protein (Bio-Rad) was prepared at a concentration of 5 mg/ml in
kinase reaction buffer.
Plasmids and Recombinant Proteins—GST-c-Jun (1–79) linked to Sepha-
rose beads was used as the substrate (40). The pcDNA3-FLAG-JNK1(APF)
and pCMV-FLAG-p38(AGF) were kindly provided by Dr. R. J. Davis (Uni-
versity of Massachusetts, Worcester (25, 41). pCMV IkBa and control empty
vector (pCMV4) were generous gifts from Dr. A. S. Baldwin Jr. (University
of North Carolina, Chapel Hill) (42, 43). pCMVERK1 was a generous gift
from Dr. D. A. Brenner (University of North Carolina, Chapel Hill) (44). IL-8
2133 CAT was described previously (15).
Paclitaxel Treatment—Cells were seeded in 100-mm plates (Falcon
Inc., Plymouth, U. K.) and grown in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% endotoxin-free fetal bovine serum until
the cells were 60–75% confluent. Immediately before treatment the
medium was removed, then cells were washed once with sterile endo-
toxin-free phosphate-buffered saline (PBS) and treated with paclitaxel
or the diluent, Me2SO stock. Paclitaxel was maintained at 270 °C at
a concentration of 30 mM. The final concentration of Me2SO never
exceeded 0.1%.
Transfection and CAT Assay—Cells from the human ovarian cancer
OVCA 420 cells were transfected using LipofectAMINE reagent (Life
Technologies, Inc.) (45). The transfection mixture was removed 6 h after
treatment. The cells were incubated in complete medium for 6 h and
then treated with Me2SO or paclitaxel for 24 h. Cell extract was pre-
pared, and CAT enzymatic activity was assayed as described elsewhere
(46, 47). To address variations in transfection efficiency, each construct
was tested using at least two separate plasmid preparations in three
independent experiments. These multiple experiments were intended
to eliminate experiment-to-experiment variations in transfection
efficiency.
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift
Assays—Nuclear extracts from OVCA 420 cells were prepared as de-
scribed previously (48), with slight modifications. Electrophoretic mo-
bility shift assays were performed as described previously (49, 50). 4–6
mg of nuclear extract was incubated with 2 mg of poly(dI-dC) and
50,000–100,000 cpm of 32P end-labeled DNA probe in a 20-ml reaction
volume. After incubation for 20 min at room temperature, the complex
was subjected to electrophoresis in a 6% nondenaturing polyacrylamide
gel containing 13 Tris-glycine. Antibody supershift experiments were
performed by preincubating 1 mg of antibody for 2 h on ice with each
binding reaction before the addition of the DNA probe.
Immunoprecipitation and Western Blot—The cell extract from OVCA
420 cells that were transfected with mutant kinase-expressing vector
was prepared in 1 ml of RIPA lysis buffer (1% Nonidet P-40, 1% sodium
deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate, pH 7.2,
2 mM EDTA, 50 mM NaF, 0.2 mM Na3VO4, 100 units/ml aprotinin). The
cell lysates were incubated on ice for 10 min. Cellular debris was
pelleted at 3,000 rpm at 4 °C for 15 min. The cell extracts were immu-
noprecipitated with anti-FLAG (5 mg/ml) antibody and then analyzed
by immunoblotting with anti-JNK1 (1.2 mg/ml), anti-p38 (1.2 mg/ml),
and control antibodies using standard techniques (51).
Photometric Sandwich ELISA for Cytoplasmic Histone-associated
DNA Fragments—105 cells were plated onto 24-well plates the day
before stimulation. Cells were incubated with paclitaxel for different
time intervals. The cells were harvested and treated with lysis buffer.
The lysate was separated into cytoplasmic and nuclear fractions by
centrifugation. 20 ml of the supernatant, which contained the cytoplas-
mic fraction, was used to measure DNA fragmentation and histone
release from the nucleus. The measurement was performed according to
the manufacturer’s protocol for the Cell Death Detection ELISAplus kit
(Boehringer Mannheim). Briefly, the supernatants were placed in
streptavidin-coated microtiter plates followed by the addition of biotin-
labeled anti-histone and peroxidase-conjugated anti-DNA antibodies.
The anti-histone antibody, bound to the plate via biotin-streptavidin,
also bound histones from released nucleosomes. The anti-DNA antibod-
ies recognized DNA in the nucleosomes and gave a colorimetric reaction
upon the addition of a photometric substrate, 2,29-azino-di[3-ethylben-
zthiazolin-sulfonate] (52, 53).
Transient Transfection and LacZ Cell Death Assay—OVCA 420 cells
were plated 24 h before transfection at a density of 2 3 103 cells/well in
a 12-well plate. Cells were cotransfected with the pCMV-bgal (0.1 mg)
plasmid, which expresses galactosidase and the plasmids containing
the super-repressor IkBa, dominant-inhibitory mutant kinase (1 mg), or
a control vector using the SuperFect transfection reagent (Qiagen,
Valencia, CA). Transfections were performed in duplicate. 6 h after
transfection, the cell medium was replaced with fresh complete medium
for 12 h, and then the cells were treated with 30 mM paclitaxel or
Me2SO. After 24 h of treatment, cells were harvested, washed, and fixed
in 0.5% glutaldehyde in PBS. These cells were washed twice with PBS,
resuspended in staining solution containing PBS (pH 7.4), 1 mM MgCl2,
10 mM K4Fe(CN)6, 10 mM K3Fe(CN)6, and 1 mM X-gal (added just before
use) for 1–3 h, and washed twice with PBS. The b-galactosidase-positive
cells in each well were counted. Cell survival was determined as the
number of blue cells in paclitaxel-treated group/number of blue cells in
Me2SO-treated group 3 100%.
Solid Phase and Immunocomplex Kinase Assay—After paclitaxel or
Me2SO treatment, the cells were washed with ice-cold PBS and lysed
with 900 ml of low salt buffer (150 mM NaCl, 20 mM Tris, pH 7.5, 5 mM
EDTA, 1% Triton X-100, 50 mM NaF, 10% glycerol, 1 mM Na3VO4, 4
mg/ml aprotinin, 20 mg/ml phenylmethylsulfonyl fluoride, 10 mg/ml leu-
peptin). The lysate was mixed in 4 °C for 15 min and centrifuged at
12,500 rpm for 12 min at 4 °C. The supernatant was transferred to a
clean tube, and 50 mg of protein was incubated with 10 mg of GST-c-Jun
(1–79) beads for 2 h at 4 °C. The beads were then washed twice with the
lysis buffer and twice with the kinase assay buffer (13 kinase assay
buffer: 20 mM HEPES, pH 7.4, 20 mM MgCl2, 20 mM b-glycerolphos-
phate containing 20 mM p-nitrophenyl phosphate, 0.1 mM Na3VO4, 2 mM
dithiothreitol). Kinase reactions were initiated by the addition of 5 ml of
7 3 kinase buffer, 0.133 ml of cold 10 mM ATP, 1 ml of [g-32 P]ATP (3,000
Ci/mmol), and H2O to a final volume of 35 ml, incubated for 20 min at
30 °C, and terminated with 7 ml of 33 SDS sample buffer. Samples were
boiled for 5 min, centrifuged at 12,500 rpm for 5 min, and then the
supernatant was resolved by 10% SDS-polyacrylamide gel electrophore-
sis. The gel was stained with Coomassie Blue and then dried. The
phosphorylation of GST-c-Jun was visualized by autography. Immuno-
complex kinase assays were carried out as described (54) with some
modifications. MAPKs were precipitated by incubation with protein
A-agarose beads (Santa Cruz) and specific antibodies (e.g. anti-JNK1,
anti-p38, or anti-ERK1 antibody) in lysis buffer (1% Nonidet P-40, 1%
sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate,
pH 7.2, 2 mM EDTA, 50 mM NaF, 0.2 mM Na3VO4, 100 units/ml apro-
tinin) for 4 h at 4 °C on a rocket platform. Immunoprecipitates were
collected by centrifugation at 2,500 rpm for 5 min at 4 °C. The precip-
itates were washed twice with lysis buffer and twice with kinase assay
buffer (50 mM HEPES, pH 7.4, 0.1 mM EDTA, 0.01% Brij 35, 0.1 mg/ml
bovine serum albumin, 0.1% b-mercaptoethanol, 0.15 M NaCl) and then
mixed with 5 mg of the indicated substrates and 10 ml of ATP mix (930
ml of kinase buffer, 6 ml of 50 mM ATP, pH 7.0, 20 ml of 2.0 M MgCl2, and
44 ml of [g-32 P]ATP at 10 mCi/ml before an incubation for 20 min at
30 °C. The reactions were terminated with SDS sample buffer and
boiled for 5 min. The supernatants were resolved by 10% SDS-poly-
acrylamide gel electrophoresis.
Immunoprecipitation Kinase Assays of p38—The p38 assay was per-
formed according to the manufacturer’s instruction for the p38 MAPK
assay (New England BioLabs, Beverly, MA). Briefly, after immunopre-
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cipitation of p38 MAPK with anti-p38 antibody (1:50 to 1:100 dilution),
the immunocomplex was incubated with ATF-2 and 200 mM cold ATP in
kinase buffer. Kinase reactions were incubated at 30 °C for 15 min and
terminated with SDS sample buffer. The products were resolved by 10%
SDS-polyacrylamide gel electrophoresis. Samples were analyzed by a
Western blot using a phospho-specific ATF-2 antibody (1:1,000 dilu-
tion). Protein bands on immunoblots were visualized by enhanced
chemical luminescence (Amersham Pharmacia Biotech).
RESULTS
Paclitaxel Activates AP-1 Binding Activity—In a previous
report, we showed that paclitaxel activates DNA binding
through the AP-1 factor in human OVCA 420 cells (15). The
results are confirmed as shown in Fig. 1, lanes 1 and 2. Pacli-
taxel-induced binding was specifically competed by an excess of
wild-type unlabeled AP-1 target site but not by an oligonucleo-
tide containing point mutations, which resulted in the loss of
AP-1 binding (lanes 3 and 4). Anti-c-Jun and anti-c-Fos anti-
bodies were used in supershift assays. The results show that an
anti-c-Jun antibody specifically diminished this DNA-protein
complex, but a control normal rabbit serum had no effect (lanes
5 and 6). Antibody directed against c-Fos protein had a small
effect and decreased binding to the level of the Me2SO control
reproducibly. Results from the cold competition and supershift
assays indicate that the DNA-protein complex formed in re-
sponse to paclitaxel contained c-Jun and probably c-Fos (Fig.
1).
JNK1 Is Activated by Paclitaxel—Because paclitaxel acti-
vates c-Jun but JNK1 activates and phosphorylates c-Jun, the
effect of paclitaxel on JNK activation is worthy of investigation.
A kinetics analysis of kinase activation by paclitaxel was first
performed. The activities of JNK, ERK, and p38 in the cell
lysates were determined by an immunocomplex kinase assay
as described under “Materials and Methods.” As shown in Fig.
2A, the activation of JNK1 activity was observed at the earliest
measured time point of 30 min at a concentration of 30 mM
paclitaxel. Importantly, this time course is coincidental with
the transcriptional activation of the IL-8 gene by paclitaxel
(14). p38-MAPK and ERK1 activity increased slightly (,1.5
fold) (Fig. 2A). Others have encountered difficulties in observ-
ing p38 activation.2 To exclude the possibility that the absence
of a significant p38 activation by paclitaxel was caused by
nonfunctional antibody or substrate, an activity assay was
performed. A specific antibody to p38 MAPK was used to im-
munoprecipitate p38 from cell lysates selectively. The resulting
immunoprecipitate was incubated with a preparation of ATF-2
fusion protein in the presence of cold ATP and kinase buffer.
The phosphorylation of ATF-1 at Thr-71 was measured by
Western blotting using a phospho-specific ATF-2 (Thr) anti-
body. Paclitaxel treatment did not increase ATF phosphoryla-
tion relative to the Me2SO control as detected by this assay.
The positive control consists of KCl-activated cells (Fig. 2B, far
right lane). This indicates that the small increase in p38 ob-
served in Fig. 2A is not caused by the assay conditions, but
likely reflects the small magnitude of response.
JNK Activation Occurs at a Low Concentration of Pacli-
taxel—Experiments were performed to determine if paclitaxel
activates JNK in a dose-dependent manner. The results show
that the activation of JNK1 activity to varying magnitude
(4.0–6.0-fold) was observed with as little as 0.1 mM paclitaxel
(Fig. 3A). This level of paclitaxel which induced JNK is easily
obtainable during chemotherapy. To extend the dose-response
analysis, lower concentrations of paclitaxel were used (Fig. 3B),
but these did not activate JNK. In contrast, ERK1 was not
strongly activated by paclitaxel. A slight induction of p38 was
reproducibly seen at a concentration of 3 mM paclitaxel in three
experiments (Fig. 3A). The concentration of paclitaxel required
2 S. E. Earp, personal communications.
FIG. 1. Paclitaxel induces AP-1 DNA binding activity. Nuclear
protein extract was prepared from OVCA 420 cells stimulated with
paclitaxel (T) (30 mM) or Me2SO (D) for 30 min. 4 mg of the extract was
mixed with 32P-labeled AP-1 DNA fragment (2130 to 2114 segment of
the IL-8 gene) in 20 ml of binding reaction buffer in the absence or
presence of unlabeled wild type (w) DNA fragment or a mutant (m)
DNA fragment. For the supershift study, 1 ml of antibody, either normal
unimmunized serum (lane 5), anti-c-Jun (lane 6), or anti-c-Fos (lane 7)
was incubated with nuclear extracts and reaction buffer on ice for 1 h
before the addition of the radiolabeled probe. The arrow indicates the
position of the AP-1 DNA-protein complex.
FIG. 2. Paclitaxel activates JNK. Panel A, paclitaxel (PTX) treat-
ment affects JNK1. Human OVCA 420 cells were treated with 30 mM
paclitaxel for 0, 30, and 60 min or Me2SO (D) for 30 min. Treated cells
were subsequently harvested, and cell lysates were prepared. Endoge-
nous JNK1, ERK1, and p38-MAPK activities (top, middle, and bottom,
respectively) were determined by immunocomplex assays using GST-c-
Jun (1–79) as JNK substrates and myelin basic protein (MBP) as ERK1
and p38-MAPK substrates as designated at the right. Panel B, pacli-
taxel failed to activate p38-MAPK. OVCA 420 cells were treated with 30
mM paclitaxel for 15 and 30 min, with 700 mM KCl for 30 min, or with
Me2SO (D) for 30 min. p38-MAPK activity was measured by Western
blotting of phospho-ATF-2 as described under “Material and Methods.”
Numbers under the bands indicate the fold activation of JNK, ERK, or
p38 as quantitated by video image densitometry. The autoradiogram
shown is from one representative experiment. This experiment was
repeated three times with comparable results.
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to activate JNK is lower than that required to induce IL-8 gene
expression (previously observed at 5–30 mM paclitaxel). This
suggests that paclitaxel can induce JNK activation efficiently
and that the induction of other factors necessary for IL-8 tran-
scription may require a higher concentration of paclitaxel.
Dominant-inhibitory Mutants of JNK Blocked IL-8 Promoter
Activation by Paclitaxel—To assess directly the involvement of
JNK or p38 in IL-8 promoter activation by paclitaxel, domi-
nant-inhibitory mutants were used. OVCA 420 cells were
transfected with FLAG-tagged dominant-inhibitory mutants of
JNK and p38 (pcDNA3-FLAG-JNK1(APF) and pCMV-Flag-
p38(AGF)) (25, 41). Transient transfected cell lysates were
immunoprecipitated with mouse monoclonal antibody to Flag
(M2) to verify the expression of dominant-inhibitory mutants.
The immunoprecipitates were examined by Western blotting
with normal rabbit serum, anti-JNK, or p38 antibodies. As
shown in Fig. 4A, transfection of the dominant-inhibitory mu-
tant of JNK resulted in the expected expression of a 46 kDa
protein, whereas transfection of the dominant-inhibitory mu-
tant of p38 produced a 38-kDa mutant protein; normal rabbit
serum did not precipitate any specific bands (Fig. 4A).
The ability of these two mutants to disrupt JNK and p38-
MAPK signaling pathway has been reported extensively in the
literature and is well characterized (25, 26, 41, 55). To deter-
mine if these dominant-inhibitory mutants can block pacli-
taxel-induced IL-8 promoter activity, an IL-8–133 CAT re-
porter construct was cotransfected (15) with one of the
following dominant-inhibitory mutants: ERK1, JNK(APF),
p38(AGF), or the appropriate empty control vectors (pcDNAs or
pCMV). As reported previously, paclitaxel increased IL-8 pro-
moter activity significantly over the Me2SO control; the intro-
duction of the empty vector (pcDNA3) did not affect this induc-
tion (Fig. 4B, first two lanes from left). Overexpression of a
dominant-inhibitory mutant of JNK1 subcloned in the pcDNA3
vector greatly reduced activation of the IL-8 CAT reporter by
paclitaxel (third lane). In the second part of the same experi-
ment, cells were transfected with an empty control vector,
pCMV, and treated with paclitaxel. This control is necessary
because the dominant-inhibitory mutants of ERK1 and p38
were subcloned in the pCMV vector. Again, paclitaxel induced
IL-8 promoter activation (fourth and fifth lanes). The cotrans-
fection of the dominant-inhibitory mutants of ERK1 had little
effect on IL-8 activation; p38 dominant-inhibitory mutant
genes had a more noticeable effect on IL-8 activation. The
super-repressor IkBa abolished all induction of the IL-8 CAT
construct. This indicates that both the JNK-mediated activa-
tion of AP-1 and NF-kB activation by paclitaxel are important
in IL-8 gene induction by the drug.
Paclitaxel-induced Activation of JNK Correlates with Cell
Death—Previous studies suggest a model in which persistently
activated JNK activity is required for inducing apoptosis. To
FIG. 3. JNK is induced by low concentrations of paclitaxel.
Panel A, OVCA 420 cells were treated with different concentrations of
paclitaxel (PTX) as indicated or Me2SO (D) for 30 min. Endogenous
JNK1, ERK1, and p38-MAPK activities (top, middle, and bottom, re-
spectively) were determined by immunocomplex assays with the sub-
strates indicated at the right. Panel B, JNK activation by different
concentration of paclitaxel in OVCA 420 cells. Numbers under the
bands are as in Fig. 2. see Fig. 2 legend. The autoradiogram shown is
from one representative experiment; the experiment was repeated
three times with comparable results.
FIG. 4. Panel A, protein expression by dominant-inhibitory JNK and
p38-MAPK mutants. Cells were transfected with pcDNA3-Flag-JNK(APF)
or pCMV-Flag-p38(AGF) as indicated. Transient transfectants were immu-
noprecipitated by using mouse monoclonal antibody to the Flag epitope
(M2), and then the immunoprecipitates were examined by Western blotting
using normal rabbit serum, JNK, and p38 antibody, respectively. The ar-
rows indicate the 46-kDa JNK1 and the 38-kDa mutant p38 protein de-
tected by JNK- and p38-specific antibodies respectively, whereas normal
rabbit serum showed no specific bands. Panel B, IL-8 promoter activation
requires JNK and NF-kB. Cells were cotransfected with a IL-8--133CAT (5
mg) reporter and dominant-inhibitory mutant kinase expressing vectors or
the super-repressor form of IkBa (10 mg) as indicated. The pCDNA3 empty
vector served as a control for the JNK(APF) plasmid and the pCMV empty
vector as a control for the ERK1, p38, and IkBa plasmids. After transfection,
OVCA 420 cells were then treated with Me2SO or 30 mM paclitaxel (PTX) for
24 h as indicated. Cell extracts were prepared, and CAT assays were per-
formed as described under “Materials and Methods.” These results repre-
sent the average 6 S.E. of three independent experiments.
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determine if this is the case, longer kinetics analysis was per-
formed to determine if a connection between rises in JNK
activity and DNA fragmentation could be observed. As shown
in Fig. 5, paclitaxel activated JNK within 30 min of treatment
and reached a maximum level at 2 h. The level then declined
slightly between 4 and 6 h (Fig. 5A). The kinetics of histone-
associated DNA fragmentation as determined by ELISA (see
“Materials and Methods”) followed that of JNK activation. Pa-
clitaxel induced significant cell death 2 h after treatment and
reached a peak at 4 h, decreasing at 6 h (Fig. 5B). These results
suggest that JNK activation precedes cell death and may play
a critical role in paclitaxel-induced cell death. To determine if
JNK is directly involved in cell death by paclitaxel, dominant-
inhibitory mutants of JNK were used in the following
experiments.
Dominant-inhibitory Mutants of JNK1 and MEKK1 Sup-
press Paclitaxel-induced Cell Death—A previous report studied
a panel of 12 paclitaxel analogs and noted a striking correlation
between the induction of IL-8 and cell death (18). We hypoth-
esize that the pathways leading to IL-8 gene activation may
also lead to cell death. Many reports have shown that JNK
activation is involved in apoptosis caused by UV, g-irradiation
(26, 27), growth factor withdrawal (30), ceramide treatment
(31), or other anti-cancer drugs (55–57). Here, we examined the
role of JNK in paclitaxel-induced cell death.
To determine whether JNK signaling contributes to pacli-
taxel-induced cell death, a b-galactosidase expression assay
was used to measure cell viability in cells transfected with a
dominant-inhibitory mutant that blocked JNK signaling.
OVCA 420 cells were cotransfected with pCMV-bgal and a
plasmid containing either a dominant-inhibitory kinase gene or
an empty vector. Each transfection was performed in duplicate.
The b-galactosidase-positive cells (blue) were stained after a
24-h exposure to paclitaxel and then counted by microscopic
examination. b-Galactosidase-positive signal was used to
measure the number of viable cells capable of producing the
gene product. Overexpression of the dominant-inhibitory mu-
tants of JNK1 (JNK1 (APF)) blocked paclitaxel-induced cell
death by approximately 80% (Fig. 5, A and B). Dominant-
inhibitory forms of MEKK1, which activates the JNK activator
SEK1, also decreased paclitaxel-induced cell death (Fig. 5B).
Transfection of the dominant-inhibitory mutant p38
((p38(AGF)) resulted in a small inhibition of cell death induced
by paclitaxel. Because NF-kB is activated by paclitaxel (15), it
is relevant to assess if molecules in the NF-kB pathway con-
tribute to paclitaxel-induced cell death. Although NF-kB is
generally thought of as a survival factor that prevents cell
death (42, 58, 59), there is also contrary evidence (60–62).
Additional experiments from another laboratory reveal that
the super-repressor IkB form did not sensitize cells to pacli-
taxel-induced death,3, but it did sensitize cells to TNF-a, a
DNA-damaging agent, and another chemotherapy (42). Fig. 6
shows that the super-repressor form of IkBa as well as the
empty vector also did not suppress paclitaxel-induced cell
death. Thus more extensive studies are necessary to clarify the
role of NF-kB in paclitaxel-induced cell death.
DISCUSSION
A previous report from our group indicates that paclitaxel
specifically induces the transcription of the IL-8 gene via acti-
vation of its promoter (14). This occurs in approximately half of
ovarian tumor cell lines and, significantly, in half of freshly
explanted tumors. The induction is by the transcriptional acti-
vation of IL-8 promoters. The paclitaxel-responsive regulatory
elements in the IL-8 promoter consist of the AP-1 and NF-kB
cognate binding sites (15). Further analysis shows that both
the AP-1 and NF-kB transcription factor are activated by pa-
clitaxel. Gel shift analysis shows that paclitaxel treatment of
ovarian tumors causes increased binding to an AP-1 cis-acting
regulatory element in the IL-8 promoter (15). This is correlated
with enhanced activation of the IL-8 promoter as well as with
the activation of a promoter with the canonical AP-1 binding
site. These findings provide a venue to examine intracellular
events that lie upstream of AP-1 which are activated by pacli-
taxel. Once these intracellular events are identified, it is then
feasible to determine if they contribute to the therapeutic ef-
fects of paclitaxel in controlling tumor growth and prolifera-
tion. The activation of these intracellular events in subsets of
tumor cells may also provide a prognostic marker that can
predict the efficacy of paclitaxel in controlling tumors in vivo.
In this report, we assess whether MAPK, ERK1, JNK1, and
p38 constitute upstream signaling events that lead to the tran-
scriptional induction of IL-8 by paclitaxel. In vitro kinase as-
says show that JNK can be activated by paclitaxel. The acti-
vation of JNK by paclitaxel suggests its potential involvement
in IL-8 induction because activated JNK is known to phospho-
rylate several transcription factors, including c-Jun, ATF2, and
TCF/Elk1 (32, 37, 38). Indeed, the JNK1 dominant-inhibitory
mutant blocked paclitaxel-induced IL-8 promoter activity (Fig.
4). These results support the conclusion that JNK-mediated
activation of c-Jun leads to IL-8 gene activation. The induction
of IL-8 has important biologic consequences in controlling tu-
3 C.-Y. Wang, personal observation.
FIG. 5. Time course of JNK activation and DNA fragmentation
in human OVCA 420 cells after treatment with paclitaxel (PTX).
Panel A, OVCA 420 cells were treated with 1 mM paclitaxel for 30 min,
1 h, 2 h, 4 h, or 6 h. JNK activities were analyzed by the immunocom-
plex kinase assay. The fold activation of JNK was calculated by com-
parison with basal JNK activities in Me2SO-treated controls. Data
shown represent the mean values from two independent experiments.
Panel B, OVCA 420 cells were incubated with paclitaxel for the indi-
cated time. Cell death was measured by the photometric ELISA assay
for cytoplasmic histone-associated DNA (see “Materials and Methods”).
The results represent the mean value from three independent
experiments.
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mor growth, as another study from our group shows that the
introduction of IL-8 into human ovarian tumors resulted in
massive granulocytic and monocytic infiltration and the subse-
quent reduction or elimination of tumor growth.4
Activation of the JNK signaling pathway is increasingly
found to play a major role in differentiation and cell death. It is
known that JNK1 is activated predominantly in response to
stress-activating signals such as growth factor withdrawal,
heat shock, osmotic, UV light, protein synthesis inhibitors, and
proinflammatory cytokines (24, 25). On the other hand, activa-
tion of the JNK pathway can also induce apoptosis or cell
death. For example, DAXX, a recently identified Fas-binding
protein, can induce apoptosis via activation of the JNK path-
way (64). The apoptosis signal-regulated kinase (ASK), is also
an activating kinase of the JNK pathway. In response to
TNF-a, ASK is sufficient to induce apoptosis and is required for
TNF-a-induced apoptosis (65). Several reports have also dem-
onstrated that the duration of JNK activation is a determining
factor for cell proliferation or death (26). Transient JNK induc-
tion, such as signaling from anti-CD28 plus phorbol 12-myris-
tate 13-acetate (PMA) or PMA plus ionomycin, causes a rapid
course of JNK1 activation leading to cell proliferation. More
sustained JNK activation (e.g. UV light, g-irradiation, DNA
damage, drug treatment) causes cell apoptosis (26, 55, 66). Our
results are consistent with the observations reported by Chen
and co-workers because paclitaxel, like other stress agents,
causes a more sustained pattern of JNK activation (Fig. 5), and
this prolonged activation of JNK is directly linked to cell death
based on the use of dominant-inhibitory JNK mutants. A wor-
thy line of investigation is to determine if JNK activation
occurs in response to microtubule stabilization by paclitaxel or
if it is independent of microtubule stabilization (66). It will be
intriguing to differentiate these molecular mechanisms of pa-
clitaxel’s action. One way to approach this may be the use of
paclitaxel analogs. Upon the examination of 12 structurally
related paclitaxel analogs, Watson et al. (18) reported a tight
correlation between paclitaxel-induced gene expression and
cell death. In their hands, paclitaxel analogs that most dramat-
ically up-regulated IL-8 expression were the most effective in
inhibiting cell survival. They also found that IL-8 production
was not directly responsible for cell killing because treatment
with anti-IL-8 antibodies failed to block cell death (18). Taken
together, all of these studies suggest that JNK activation is
required for both IL-8 gene transcription and cell killing.
The p38 kinase pathway that is activated by many stimuli
common to the JNK/SAPK pathway is activated to a lesser
degree in paclitaxel-treated human ovarian cancer cells (25, 67,
4 L.-F. Lee, R. P. Hellendall, Y. Wang, J. S. Haskill, N. Mukaida, K.
Matsushima, and J. P.-Y. Ting, submitted for publication.
FIG. 7. The signaling pathway of paclitaxel-induced gene ex-
pression and cell death. The activation of JNK by paclitaxel is a
converging point for drug-induced cell death and in the activation of
IL-8. Paclitaxel treatment leads to JNK activation, which in turn leads
to AP-1 activation. AP-1 together with NF-kB, which is also induced by
paclitaxel, result in IL-8 promoter activation. JNK is also involved in
cell death induced by paclitaxel as shown by the dominant-inhibitory
JNK mutants.
FIG. 6. Dominant-inhibitory JNK1 and MEKK1 mutants block
paclitaxel-induced cell death. Panel A, OVCA 420 cells were co-
transfected with pCMVb-Gal (0.1 mg/12-well plate) and either an empty
expression vector control or with vector encoding mutant kinase or
IkBa (1 mg). After 6 h of transfection, the medium was replaced with
fresh complete medium, and the cells were incubated for 12 h and then
treated with 30 mM paclitaxel (PTX) or Me2SO (DMSO). After 24 h of
treatment, cells were fixed and stained with X-gal, and b-galactosidase-
positive cells in each well were counted. Cell survival was determined
by the percentage of blue cells in the paclitaxel-treated group divided by
the percentage of blue cells in Me2SO-treated group multiplied by
100%. The results shown here represent the mean 6 S.D. of three
independent experiments performed in duplicate. Panel B, X-gal color-
imetric staining of vector-, or JNK(APF), or IkBa-transfected cells
treated with paclitaxel or Me2SO. All panels are magnified 3 40.
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68). Transfection of the dominant-inhibitory mutant p38
(p38(AGF)) resulted in a small inhibition of IL-8 promoter CAT
activity and cell death induced by paclitaxel. In composite,
these data point to a role for p38 in all of these assays. During
the preparation of this manuscript, another report showed that
paclitaxel primarily affected JNK activation but not p38-
MAPK activation in B lymphoblasts (57). Thus the effect of
paclitaxel on p38 is likely slight.
An earlier study also showed that IL-8 induction by pacli-
taxel requires activation of the NF-kB transcription factor (15).
Recent work from several laboratories has demonstrated that
the Rel/NF-kB transcription factor regulates apoptosis by serv-
ing as a survival signal in many cell types (42, 58, 59). Fur-
thermore, Wang et al. (42) have shown that cells transfected
with the super-repressor IkBa, which inactivates NF-kB, are
more prone to cytotoxicity in response to pro-apoptotics includ-
ing the inflammatory cytokine TNF-a and the DNA-damaging
agents, ionizing radiation and daunorubicin.
Like many other activators of the cell stress response, pacli-
taxel activates both AP-1 and NF-kB signaling pathways and
induces cell death (15). Similar divergent signaling via the
TNF-a receptor is well characterized, involving separate acti-
vation of cell death pathways (through the TNF-a receptor-
associated factor Traf1) and cell survival pathways through the
NF-kB-activating factor Traf2 (69). Inhibition of Traf-2-
dependent signaling potentiates TNF-a-induced apoptosis (70).
Similarly, in addition to its role in AP-1 signaling, the JNK
activator MEKK1 is implicated in activation of NF-kB (71–73),
although the mechanism of NF-kB activation by MEKK1 re-
mains unclear. Thus, stress signaling involving MEKK1 and
TNF-a (and likely paclitaxel and other stress stimulators) ap-
pears to involve a balance of death and survival pathways, the
final outcome of which may depend on quantitative, combina-
torial, or temporal considerations. In support of this, activation
of caspases during Fas-stimulated apoptosis blocks subsequent
TNF-a-mediated destruction of IkBa and is coincident with
complete cleavage of MEKK1 by caspase(s) to a cytosoluble,
pro-apoptotic form (63). The dual activation of NF-kB and JNK
by paclitaxel may similarly involve a balance between these
two signals with likely opposite effects on cell survival. On the
other hand, NF-kB-mediated signals that regulate the process
of apoptosis are likely complex. For example, under some cir-
cumstances, activation of NF-kB may also promote apoptosis
(60-62). In one study (61), apoptotic death induced by serum
withdrawal was shown to be accompanied by NF-kB activation
in a human embryonic kidney cell line. Interestingly, their
results show that the transient or stable expression of bcl-2,
which is known to interfere with apoptosis, reduced kB-depend-
ent reporter gene expression and reduced cell death. Thus the
role of NF-kB as a promoter or attenuator of cell death may
ultimately depend on both the cell type and the nature of the
apoptosis-inducing stimuli.
In addition to the importance of JNK in paclitaxel-induced
cell death, we have recently observed that DEVD (Z-Asp-Glu-
Val-Asp-fluoromethyl ketone), which is known to inhibit
caspase-3/CCP32, and the broad spectrum caspase, inhibitor
VAD (Z-Val-Ala-Asp- fluoromethyl ketone), efficiently block pa-
clitaxel-induced histone-associated DNA fragmentation in hu-
man ovarian cell lines. However, these caspase inhibitors do
not significantly affect JNK activation.5 These results suggest
that the caspase cascade plays a critical role in paclitaxel-
mediated apoptosis but may be located downstream of JNK
signaling or may represent an additional route of apoptosis.
In summary, this report is the first to show that JNK is
directly involved in paclitaxel-induced IL-8 transcription acti-
vation and cell death as summarized by the model in Fig. 7. In
this model, paclitaxel treatment leads to the activation of JNK,
which is important both in the activation of AP-1 and in caus-
ing cell death. Paclitaxel also activates NF-kB, which together
with AP-1, leads to the activation of IL-8 genes. Thus, intra-
cellular signals that are induced by paclitaxel may play signif-
icant roles in mediating the clinical efficacy of this drug and are
worthy of further in-depth analysis. The involvement of JNK in
paclitaxel-mediated cell death suggests that artificially en-
hancing JNK activation may be of value in enhancing the
therapeutic efficacy of paclitaxel or in treating non-paclitaxel-
responsive tumors.
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